Skip to content

Prospective Evaluation of Patient Reported Xerostomia After Whole Brain Radiation

Prospective Evaluation of Patient-Reported Xerostomia After Whole Brain Radiation

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02682199
Acronym
NRR
Enrollment
100
Registered
2016-02-15
Start date
2015-10-31
Completion date
2018-08-30
Last updated
2019-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Xerostomia

Brief summary

The goal of this prospective observational study is to investigate whether whole brain radiation leads to measurable xerostomia from parotid gland toxicity.

Detailed description

The parotids have not been traditionally considered an organ at risk / avoidance structure in whole brain radiation. However, patients receiving whole brain radiation sometimes complain of dry mouth. Investigators hypothesize that standard whole brain radiation fields cause an acute measurable increase in xerostomia at one month post-radiation, and that the severity of xerostomia is related to the dose received by the parotids. In this study, investigators will use the validated University of Michigan Xerostomia Questionnaire to prospectively collect baseline and post-radiation xerostomia scores up to 6 months after treatment. The radiation dose to the parotids will be evaluated to assess whether there is a dose-toxicity relationship. Investigators anticipate a total accrual of 60 patients with a goal of 48 evaluable patients.

Interventions

None listed

Sponsors

UNC Lineberger Comprehensive Cancer Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* Patients to be treated with whole brain radiation in 10-15 fractions to a total dose of 25-37.5 Gy for a diagnosis of brain metastases from any disease site or as prophylaxis in the treatment of potentially subclinical intracranial disease (e.g. from small cell lung cancer). * Has not had prior radiation that would have exposed the parotids to a significant (estimated \>10 Gy mean parotid dose) level of radiation within the past one year. Patients receiving prior stereotactic radiosurgery for brain metastasis are eligible for inclusion in this trial as this form of radiation is highly conformal and exposes the parotids to minimal (estimated \<1 Gy) radiation. * Greater than or equal to 18 years of age (no upper age limit). * Informed consent obtained.

Exclusion criteria

* Patients receiving whole brain radiation without the use of a CT-based planning simulation. * Patients who are on medications known to cause dry mouth, such as anticholinergics. * Physically unable to communicate by paper or phone to complete the study survey. * Prisoners.

Design outcomes

Primary

MeasureTime frame
Measureable acute increase in xerostomiabaseline to 1 month post-treatment

Secondary

MeasureTime frame
Association of degree of change in xerostomia score and the radiation dose received by the parotid glandsbaseline to 1 month post-RT
Effect of whole brain radiation on the time course of xerostomiabaseline and four post-radiation time points (procedure, 1 month post-RT, 3 months post-RT, 6 months post-RT).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026